SUBSCRIBE
SUBSCRIBE

GSK Bio

NEWS
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
While Mylan and Teva Continue Bickering, Perrigo Snaps Up OTC Portfolio From GlaxoSmithKline
June 2, 2015
 · 
7 min read
ASCO15: Bristol Myers Cancer Drug Combo Shrinks 60% of Melanomas, As Oncology Roars
Drug Development
ASCO15: Exelixis Results for Drug Combo Buoy the Flailing SF Biotech
June 1, 2015
 · 
3 min read
ASCO15: Bristol Myers Cancer Drug Combo Shrinks 60% of Melanomas, As Oncology Roars
Drug Development
ASCO15 EXCLUSIVE: Cancer Drug Could Be Next New Melanoma Med Approved by FDA, Says Genentech Exec
June 1, 2015
 · 
4 min read
ASCO15: Bristol Myers Cancer Drug Combo Shrinks 60% of Melanomas, As Oncology Roars
Drug Development
ASCO15 EXCLUSIVE: Genentech VP Tells BioSpace Gazyva a “Clear Advance” For NHL Treatment
June 1, 2015
 · 
4 min read
ASCO15: Bristol Myers Cancer Drug Combo Shrinks 60% of Melanomas, As Oncology Roars
Drug Development
ASCO15: BioSpace’s Roundup of What You May Have Missed at ASCO So Far
June 1, 2015
 · 
5 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Pfizer Split Could Come as Early as 2015-2016, J.P. Morgan Says
June 1, 2015
 · 
3 min read
ASCO15: Bristol Myers Cancer Drug Combo Shrinks 60% of Melanomas, As Oncology Roars
Drug Development
ASCO15 EXCLUSIVE: Merck & Co.’s Breast Cancer Drug Beats Chemo Rates and Will Roll Into Phase III, Says Investigator
June 1, 2015
 · 
3 min read
ASCO15: Bristol Myers Cancer Drug Combo Shrinks 60% of Melanomas, As Oncology Roars
Drug Development
ASCO15: Tiny Clovis Oncology Becomes an Even Bigger Takeover Target as Ovarian Cancer Drug Shrunk Tumors in 82% of Women
June 1, 2015
 · 
5 min read
ASCO15: Bristol Myers Cancer Drug Combo Shrinks 60% of Melanomas, As Oncology Roars
Drug Development
ASCO15: Pfizer’s Ibrance Slows Progression of Breast Cancer in Late-Stage Study
June 1, 2015
 · 
4 min read
Load More
  • 2026 - Best Places to Work - Badge (1).png
JOBS
IN THE PRESS
Press Releases
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
May 28, 2025
 · 
9 min read
Press Releases
Vesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson’s Disease
November 12, 2024
 · 
4 min read
Press Releases
Expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine approved in Canada for adults aged 50-59 at increased risk
November 5, 2024
 · 
7 min read
Press Releases
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
October 8, 2024
 · 
10 min read
Pharm Country
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
March 7, 2024
 · 
5 min read
Pharm Country
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
August 17, 2023
 · 
6 min read
Deals
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
May 16, 2023
 · 
7 min read
Business
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
December 2, 2022
 · 
5 min read